Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oramed Pharmaceuticals has received an Australian patent, which covers vital part of the core technology that allows for the oral delivery of peptides.
Subscribe to our email newsletter
Oramed’s core product is an oral insulin capsule. An oral delivery system for insulin may increase patient value, leading to a healthier lifestyle, the company said.
Higher patient compliance is expected to result in improved patient outcomes and a reduction in the costs of healthcare and lost productivity.
Oramed CEO Nadav Kidron said that their patent position further strengthens Oramed and their competitive advantage in the development of an oral insulin capsule.
"The patent received will provide additional commercial protection for Oramed’s technology and adds extended value to our existing IP-portfolio," Kidron added.